Jump to main content.


Hexachlorocyclopentadiene (HCCPD) Quickview (CASRN 77-47-4)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for Hexachlorocyclopentadiene (HCCPD)

File First On-Line: 01/31/1987; Last Significant Revision: 07/05/2001

Category (section)
Status
Last Revised
Oral RfD Assessment On-line 07/05/2001
Inhalation RfC Assessment On-line 07/05/2001
Carcinogenicity Assessment On-line 07/05/2001
Synonyms
  • 77-47-4
  • C-56
  • Graphlox
  • HCCP
  • HCCPD
  • HEX
  • Hexachloro-1,3-cyclopentadiene
  • Hexachloropentadiene
  • PCL
  • Perchlorocyclopentadiene
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect
Point of Departure*
UF RfD
Chronic irritation BMDL10 : 6 mg/kg-day 1000 6 x10-3 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page


Reference Concentration for Chronic Inhalation Exposure (RfC)

Critical Effect
Point of Departure*
UF RfC
Suppurative inflammation of the nose NOAEL (HEC): 2.4 x10-2 mg/m3 100 2x10-4 mg/m3

* The Point of Departure listed serves as a basis from which the Inhalation RfC was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • E (Evidence of non-carcinogenicity for humans)
    • Not likely to be carcinogenic to humans
  • Weight-of-Evidence Narrative:
    • According to the existing Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986a), evaluation of the weight-of-evidence for carcinogenicity to humans indicates that HCCPD is most appropriately categorized as Group E, Evidence of Noncarcinogenicity to Humans, via inhalation exposure. In accordance with U.S. EPA's Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), HCCPD is not likely to be a human carcinogen by the inhalation route based on current data indicating no evidence of cancer in well-conducted bioassays in two species of rodents; the absence of increased deaths from cancer in the limited human occupational studies available; and lack of mutagenicity in a variety of test systems.
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

  • Not Assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

  • Not Assessed under the IRIS Program.

Top of page


Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research


Local Navigation


Jump to main content.